Search Within

Martin Stuart Tallman

  1. "GSK Faculty"
Formats
  1. Meeting Abstract (88)
  2. Journal Article (68)
  3. Book Section (2)
  4. Guidelines (2)
  5. Research Letter (2)
  6. Review (2)
Groups
  1. Adult Leukemia (164)
  2. Center for Hematologic Malignancies (164)
  3. Department of Medicine (164)
  4. GSK Faculty (164)
  5. Hematologic Malignancies, Division of (164)
  6. Executive Committee, Center for Hematologic Malignancies (156)

More Groups

People
  1. Ross Levine (131)
  2. Omar Abdel-Wahab (68)
  3. Jae Park (36)
  4. Eytan Stein (35)
  5. Maria Arcila (31)
  6. Raajit Rampal (29)

More People

Years
  1. 2024 (1)
  2. 2023 (6)
  3. 2022 (8)
  4. 2021 (8)
  5. 2020 (16)
  6. 2019 (13)

More Years

Publications
  1. Blood (83)
  2. Haematologica (8)
  3. Blood Advances (7)
  4. Leukemia Research (6)
  5. Cancer Research (5)
  6. Cancer Discovery (4)

More Publications

Publishers
  1. American Society of Hematology (90)
  2. Nature Publishing Group (14)
  3. American Association for Cancer Research (9)
  4. Ferrata Storti Foundation (8)
  5. Cell Press (6)
  6. Elsevier Ltd (6)

More Publishers

Results (164)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • A JAK2/IDH1-mutant MPN clone unmasked by ivosidenib in an AML patient without antecedent MPN
    Journal Article

    Xiao, W.; Miles, L. A.; Bowman, R. L.; Durani, V.; Tian, H. S.; DelGaudio, N. L.; Mishra, T.; Zhu, M.; Zhang, Y.; Stump, S. E.; more...
    Blood Advances (2020)

    Fulltext@MSK | Save
  • Cancer therapy shapes the fitness landscape of clonal hematopoiesis
    Journal Article

    Bolton, K. L.; Ptashkin, R. N.; Gao, T.; Braunstein, L.; Devlin, S. M.; Kelly, D.; Patel, M.; Berthon, A.; Syed, A.; Yabe, M.; more...
    Nature Genetics (2020)

    Fulltext@MSK | Save
  • Effects of radiation therapy on clonal hematopoiesis
    Meeting Abstract

    Modlin, L. A.; Wijetunga, N. A.; Patel, M.; Gao, T.; Ptashkin, R.; Sullivan, M. R.; Kelly, D. W.; Caltabellotta, N.; Solit, D. B.; Berger, M. F.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • Leukemia cell of origin influences apoptotic priming and sensitivity to LSD1 inhibition
    Journal Article

    Cai, S. F.; Chu, S. H.; Goldberg, A. D.; Parvin, S.; Koche, R. P.; Glass, J. L.; Stein, E. M.; Tallman, M. S.; Sen, F.; Famulare, C. A.; more...
    Cancer Discovery (2020)

    Fulltext@MSK | Save
  • The Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of acute leukemia
    Guidelines

    Boyiadzis, M. M.; Aksentijevich, I.; Arber, D. A.; Barrett, J.; Brentjens, R. J.; Brufsky, J.; Cortes, J.; De Lima, M.; Forman, S. J.; Fuchs, E. J.; more...
    Journal for ImmunoTherapy of Cancer (2020)

    Fulltext@MSK | Save
  • TGFβR-SMAD3 signaling induces resistance to PARP inhibitors in the bone marrow microenvironment
    Journal Article

    Le, B. V.; Podszywalow-Bartnicka, P.; Maifrede, S.; Sullivan-Reed, K.; Nieborowska-Skorska, M.; Golovine, K.; Yao, J. C.; Nejati, R.; Cai, K. Q.; Caruso, L. B.; more...
    Cell Reports (2020)

    Fulltext@MSK | Save
  • Safety and activity of selinexor in patients with myelodysplastic syndromes or oligoblastic acute myeloid leukaemia refractory to hypomethylating agents: A single-centre, single-arm, phase 2 trial
    Journal Article

    Taylor, J.; Mi, X.; Penson, A. V.; Paffenholz, S. V.; Alvarez, K.; Sigler, A.; Chung, S. S.; Rampal, R. K.; Park, J. H.; Stein, E. M.; more...
    The Lancet Haematology (2020)

    Fulltext@MSK | Save
  • Erythroid/megakaryoblastic leukemia with TP53 and RUNX1 mutations frequently occurs in blast transformation of Philadelphia chromosome-negative myeloproliferative neoplasms: A single-institution experience with 56 cases
    Meeting Abstract

    Liu, Y.; Mata, D.; Baik, J.; Famulare, C.; Sigler, A.; Arcila, M.; Zhang, Y.; Dogan, A.; Tallman, M.; Levine, R.; more...
    Laboratory Investigation (2020)

    Fulltext@MSK | Save
  • Frequent RUNX1 and TP53 mutations in secondary acute myeloid leukemia with mixed phenotype
    Meeting Abstract

    Galera, P.; Baik, J.; Famulare, C.; Sigler, A.; Zhang, Y.; Arcila, M.; Dogan, A.; Tallman, M.; Levine, R.; Glass, J.; more...
    Laboratory Investigation (2020)

    Fulltext@MSK | Save
  • First line chemo-free therapy with the BRAF inhibitor vemurafenib combined with obinutuzumab is effective in patients with HCL
    Meeting Abstract

    Park, J. H.; Shukla, M.; Salcedo, J. M.; Vemuri, S.; Kinoshita, J. C.; Smith, M. D.; Winer, E. S.; Abdel-Wahab, O.; Tallman, M. S.
    Blood (2019)

    Fulltext@MSK | Save